LKB1 suppresses growth and promotes the internalization of EGFR through the PIKFYVE lipid kinase

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• The tumor suppressor Liver kinase B1 (LKB1) is a serine/threonine protein kinase.
• LKB1 mutations are common in human lung adenocarcinoma (LUAD), a major cancer type.
• LKB1's role in regulating cell polarity and metabolism is known, but its tumor suppressive pathways are not fully understood.

Approach:

• Developed a spheroid-based cell culture assay to study LKB1-dependent growth.
• Utilized genome-wide CRISPR screens to identify LKB1-regulated pathways.
• Validated findings using orthogonal experimental methods.

Key Points:

• LKB1 suppresses tumor growth through a novel mechanism involving PIKFYVE lipid kinase activation.
• Activated PIKFYVE promotes the internalization of wild-type Epidermal Growth Factor Receptor (EGFR).
• This identifies a new regulatory pathway for EGFR signaling.

Conclusions:

• Discovered a previously undefined mechanism by which LKB1 suppresses growth in lung adenocarcinoma.
• Findings highlight the PIKFYVE-EGFR axis as a potential therapeutic target.
• This research may inform new treatment strategies for patients with LKB1-mutant LUAD.